Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

被引：0

作者：

Jung, Sung-Hoon ^{[1
]}

Lee, Je-Jung ^{[2
]}

Kim, Mihee ^{[3
]}

Min, Chang-Ki ^{[4
]}

Lee, Ji Yun ^{[5
]}

Jo, Jae-Cheol ^{[6
]}

Yoon, Sung-Soo ^{[7
]}

Lim, Sung-Nam ^{[8
]}

Do, Young Rok ^{[9
]}

Kim, Kihyun ^{[10
]}

Lee, Jae Hoon ^{[11
]}

Yoo, Kwai Han ^{[11
]}

Bae, Sung Hwa ^{[12
]}

Yi, Jun Ho ^{[13
]}

Jung, Jongheon ^{[14
]}

Eom, Hyeon-Seok ^{[15
]}

机构：

[1] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Sch Med, Hwasun, South Korea

[2] Kyungpook Natl Univ, Dept Hematol Oncol, Sch Med, Kyungpook Natl Univ Hosp, Daegu, South Korea

[3] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea

[4] Seoul St Marys Hosp, Seoul, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[6] Ulsan Univ Hosp, Ulsan, South Korea

[7] Seoul Natl Univ, Coll Med, Seoul, South Korea

[8] Inje Univ, Coll Med, Haeundae Paik Hosp, Busan, South Korea

[9] Keimyung Univ, Dept Hematooncol, Dongsan Med Ctr, Daegu, South Korea

[10] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[11] Gachon Univ, Gil Med Ctr, Seongnam, South Korea

[12] Daegu Catholic Univ Hosp, Daegu, South Korea

[13] Chung Ang Univ Hosp, Seoul, South Korea

[14] Natl Canc Ctr, Goyang, South Korea

[15] Natl Canc Ctr Korea, Dept Internal Med, Goyang, South Korea

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-144

引用

页码：S115 / S115

页数：1

共 50 条

[21] High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
Sivaraj, D.
Bacon, W.
Long, G. D.
Rizzieri, D. A.
Horwitz, M. E.
Sullivan, K. M.
Kang, Y.
Li, Z.
Chao, N. J.
Gasparetto, C.
BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 34 - 38
[22] Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen
Hagen, Patrick
D'Souza, Anita
Hari, Parameswaran
Davila, Omar
Zhang, Mei-Jie
Vesole, David H.
Smith, Scott E.
Rodriguez, Tulio E.
Stiff, Patrick J.
BLOOD, 2019, 134
[23] High-Dose Melphalan Versus Busulfan, Cyclophosphamide As Conditioning Regimens for Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Styler, Michael
Crilley, Pamela Ann
Jain, Maneesh
Ward, Kristine
Topolsky, David
Cho, David
Kim, Marc
BLOOD, 2015, 126 (23)
[24] Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma
Ria, R
Falzetti, F
Ballanti, S
Minelli, O
Di Lanni, M
Cimminiello, M
Vacca, A
Dammacco, F
Martelli, MF
Tabilio, A
HEMATOLOGY JOURNAL, 2004, 5 (02) : 118 - 122
[25] Autologous stem cell transplantation with high dose melphalan conditioning regimen is safe for elderly multiple myeloma patients
Czyz, Anna
Szeremet, Agnieszka
Bogucka-Fedorczuk, Aleksandra
Majcherek, Maciej
Rybka, Justyna
Prajs, Iwona
Wrobel, Tomasz
BONE MARROW TRANSPLANTATION, 2019, 54 : 499 - 500
[26] High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
Benson, Don M., Jr.
Elder, Patrick J.
Lin, Thomas S.
Blum, William
Penza, Sam
Avalos, Belinda
Copelan, Edward
Farag, Sherif S.
LEUKEMIA RESEARCH, 2007, 31 (08) : 1069 - 1075
[27] Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen
Hagen, Patrick
D'Souza, Anita
Hari, Parameswaran
Davila, Omar
Zhang, Mei-Jie
Vesole, David H.
Smith, Scott E.
Rodriguez, Tulio E.
Stiff, Patrick J.
LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3484 - 3492
[28] Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
M. Blanes
J. I. Lorenzo
P. Ribas
A. Jiménez
J. D. González
M. J. Cejalvo
C. Solano
A. Alegre
Javier de la Rubia
Annals of Hematology, 2019, 98 : 2013 - 2015
[29] Velcade and high-dose melphalan: a new preparative regimen before autologous stem cell transplantation for multiple myeloma
Danho, C
Huynh, A
Roussel, M
Ysebaert, L
Recher, C
Huguet, FR
Nouvel, C
Laurent, G
Attal, M
BONE MARROW TRANSPLANTATION, 2006, 37 : S137 - S137
[30] Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
Blanes, M.
Lorenzo, J. I.
Ribas, P.
Jimenez, A.
Gonzalez, J. D.
Cejalvo, M. J.
Solano, C.
Alegre, A.
de la Rubia, Javier
ANNALS OF HEMATOLOGY, 2019, 98 (08) : 2013 - 2015

← 1 2 3 4 5 →